APG Asset Management US’s Neurocrine Biosciences NBIX Stock Holding History

APG Asset Management US’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,087	Closed	-$286K	–	135
2025 Q3	$286K	Hold	2,087	–	–	﹤0.01%	176
2025 Q2	$267K	Hold	2,087	–	–	﹤0.01%	183
2025 Q1	$223K	Hold	2,087	–	–	﹤0.01%	198
2024 Q4	$285K	Sell	2,087 -224	-10%	-$27.7K	﹤0.01%	194
2024 Q3	$264K	Sell	2,311 -25,642	-92%	-$3.52M	﹤0.01%	153
2024 Q2	$3.92M	Buy	27,953 +721	+3%	+$98.9K	0.02%	154
2024 Q1	$3.85M	Buy	27,232 +8,698	+47%	+$1.19M	0.02%	159
2023 Q4	$2.44M	Buy	+18,534	New	+$2.13M	0.02%	169

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

APG Asset Management US's NBIX Position: Q4 2025 in Review

APG Asset Management US sold out of Neurocrine Biosciences (NBIX) in Q4 2025, closing a stake of 2,087 shares — an estimated $286K sold.

APG Asset Management US first reported a position in NBIX in Q4 2023 and held it in 8 quarters. The position peaked at $3.92M in Q2 2024. 733 funds tracked by Wall St. Rank hold NBIX as of Q4 2025.

APG Asset Management US reported no remaining Neurocrine Biosciences position as of Q4 2025 after selling out during the quarter.
APG Asset Management US sold 2,087 Neurocrine Biosciences shares in Q4 2025, an estimated $286K.
APG Asset Management US first reported a position in Neurocrine Biosciences in Q4 2023 and held it in 8 quarters.
APG Asset Management US's Neurocrine Biosciences position peaked at $3.92M in Q2 2024.
733 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2025.

Based on APG Asset Management US's 13F filing for Q4 2025, filed 12 Feb 2026.